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ABSTRACT
Cyclosporin A (CsA) is the prototype of immunosuppressant drugs that have revolutionized the management of all transplantation and
autoimmune diseases. Side effects of CsAmainly affecting the kidney but also observed in liver and heart, limit the therapeutic use of this drug
after organ transplantation. The renal toxicity of CsA is attributed to reduced renal blood ﬂow which leads to hypoxia-reoxygenation injury
accompanied by excessive generation of oxygen-derived free radicals. In several therapeutic protocols, CsA is used in association with
corticosteroids to obtain better therapeutic results. Recently, our studies showed that hydrocortisone (HY) has a protective effect on CsA-
induced cardiotoxicity. In fact our previous results demonstrated that in rat cardiomyocytes, CsA toxicity is due to a calcium overload, which
in turn induce lipid peroxidation and determines oxidative stress-induced cell injury. Treatment with HY effectively inhibits CsA-induced
toxicity, decreasing lipid peroxidation as well as calcium intracellular concentration. In this study we evaluated in vivo the effects of CsA,
used alone or in association with HY, on some parameters of renal dysfunction (blood urea nitrogen; BUN, creatinine, and cholesterol),
malondialdheyde (MDA) levels, antioxidant enzyme catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), and apoptosis.
CsA administration for 24 days resulted in a marked renal oxidative stress, which signiﬁcantly deranged the renal functions. Treatment with
CsA in association with HY signiﬁcantly improved the renal dysfunction and renal oxidative status. This study clearly suggests the role of
oxidative stress in the pathogenesis of CsA-induced nephrotoxicity. J. Cell. Biochem. 103: 997–1004, 2012.  2011 Wiley Periodicals, Inc.
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C yclosporin A (CsA) is a powerful immunosuppressive drugthat is widely used to prevent organ rejection and to treat
certain autoimmune disease [Hagar et al., 2006]. However, CsA
treatment is often limited by severe adverse effects such as
hypertension and nephrotoxicity [Banijamali et al., 1993; Taler
et al., 1999]. Adverse renal effects of CsA can be divided into two
categories: functional and histological abnormalities. CsA-induced
renal dysfunction is related to reduced glomerular ﬁltration rate and
renal blood ﬂow. This is generally thought to be secondary to
vasoconstriction of the glomerular afferent arterioles, which causes
a decrease in glomerular pressure [Andoh and Bennett, 1998]. Renal
dysfunction, in turn, causes an increase in serum creatinine
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concentration and a decrease in creatinine clearance. These
functional changes are dose-dependent and are usually reversible
after short-term CsA treatment [Banijamali et al., 1993]. CsA-
induced histological renal damage is mainly characterized by
tubulointerstitial ﬁbrosis of striped pattern and arteriolopathy of
the afferent arterioles [Antonovych et al., 1988]. Interstitial
ﬁbrosis consists of streaks of ﬁbrosis. Arteriolopathy is character-
ized by luminal narrowing and arteriolar wall thickening. These
changes are composed of subendothelial edema, swelling of
hypertrophied endothelial cells protruding into the lumen and
eosinophilic granular transformation of vascular smooth muscle
cells [Antonovych et al., 1988]. Moreover, the use of CsA is also
reported to be related to increased vasoconstriction and vascular
endothelial dysfunction [Stephan et al., 1995]. The exact mechanism
of CsA-induced hypertension and nephrotoxicity remain obscure.
Experimental studies revealed that several mechanisms may be
involved. These include activation of the renin–angiotensin
system (RAS) [Edwards et al., 1994] and increased synthesis of
endothelins [Fogo et al., 1992]. Several studies suggest that a
defect in intracellular calcium handling [Lo Russo et al., 1996],
magnesium deﬁciency [Mervaala et al., 1997], oxidative stress
[De Nicola et al., 1993], and nitric oxide system [Navarro-Antolin
et al., 1998] are involved. Although there are several possible
mechanism of CsA-induced nephrotoxicity, it has been proposed
that CsA-related toxicity may in part be due to excessive
generation of reactive oxygen species (ROS) [Wang and
Salahudden, 1994; Wolf et al., 1997]. Furthermore, cell and tissue
lipid peroxidation induced by cyclosporin as well as the release of
ROS has recently been pointed out to be the factors responsible
for the toxic phenomena related to the administration of
cyclosporin [Longoni et al., 1999]. Several lines of evidence
suggest that CsA-induced renal and cardiovascular toxicity may be
due to oxidative stress. In fact, CsA increases hypoxia and free
radical production in the rat kidney [Zhong et al., 1998].
Antioxidants, such as a-tocopherol, ascorbate, lazaroids, and
superoxide dismutase (SOD)/catalase (CAT), have been shown to
decrease CsA-induced renal toxicity [Wang and Salahudden, 1994].
In several therapeutic protocols CsA is used in association with
corticosteroids to obtain better therapeutic results. In fact, many
evidence suggest that the hydrocortisone (HY), a steroidal anti-
inﬂammatory drug is able to reduce lipid peroxidation induced in
rat by ligated loop of the distal ileum [Otamiri, 1989] or in the
rat hyppocampus under stress conditions [Tolstuckima et al.,
1999]. HY also has a strong immunosuppressive activity. It evokes
immunosuppression by inducing apoptosis of T lymphocytes by
activating supposed lysis genes or by repressing the gene expression
required for proliferation and growth [Cohen, 1991]. Our previous
research demonstrated that, in rat cardiomyocytes, HY effectively
inhibits CsA-induced toxicity [Florio et al., 2003] and that the
balance between lipid peroxidation products and nitric oxide
production may play a key role to increase drug-induced
cytotoxicity [Pacilio et al., 1998; Pagnini et al., 2000a, 2000b].
With this in mind, the aim of the present study was to evaluate in
vivo in kidney tissue the effects of CsA used alone or in association
with HY on some parameters of renal dysfunction, on oxidative
stress and apoptosis.
MATERIALS AND METHODS
ANIMALS
Adult male Wistar rats weighing 180–200 g (Harlan-Nossan-Milan,
Italy) were housed in a 12-h dark/light cycle animal facility with
controlled temperature and humidity. Food and water were given ad
libitum throughout the study. Every effort was made to minimize
animal suffering and the studies were performed according to Italian
Law on the protection of laboratory animals ‘‘Decreto legislativo n.
116 del 27/01/1992. Attuazione della direttiva (CEE) n. 609/86 in
materia di protezione degli animali utilizzati a ﬁni sperimentali o ad
altri ﬁni scientiﬁci,’’ all procedures were approved by the Italian
Ministry of Health.
CHEMICALS
CsA (Sandimmun) was obtained from Novartis Farma S.p.A.
(Origgio, Varese, Italy); HY and Malondiadheyde were purchased
from Sigma (Milan, Italy). The drug solutions were freshly prepared
and used on the same day.
EXPERIMENTAL PROTOCOL
The rats were randomized and divided into four groups of 10
animals each and were treated for 24 days as follows: the ﬁrst group
(control) received a daily equivalent volume of vehicle for CsA,
castor oil, subcutaneously (s.c.). The second group received CsA
(25mg/kg/s.c./die/2ml) dissolved in castor oil, the third group
received intraperitoneally (i.p.) HY (5mg/kg/i.p./die/2ml); the
fourth group received CsA (25mg/kg/s.c./die/2ml) associated to
HY (5mg/kg/i.p./die/2ml). Diastolic blood pressure (DBP) and
systolic blood pressure (SBP) was measured from the tail of the
animals using a blood pressure recorder (BP Recorder mod. LE 5002
Ugo Basile, Italy) on days 0–6–12–18–24. The animals were adapted
to the BP recording for at least 5 days before starting the
experiments. Twenty-four hours after last treatment, the animals
were sacriﬁced and blood was collected for various biochemical
assay. A midline abdominal incision was performed and both the
kidneys were isolated, the left kidney was immediately removed and
stored at708C for the estimation of lipid peroxidation, glutathione
peroxidase (GPx), CAT SOD activity, and apoptosis. The right kidney
was ﬁxed in 10% neutral-buffered formalin for histological studies.
The blood was collected through abdominal aorta. The blood
samples were processed to harvest the BUN, creatinine, and
cholesterol and were assayed using standard diagnostic kits (Sigma).
RENAL TISSUE PREPARATION
Renal tissue was homogenized in a solution of 50mM potassium
phosphate, 0.1% Triton (pH 7.0). Crude homogenates were
centrifuged at 15,300 rpm for 30min at 48C and used to assess
antioxidant enzyme activities, tissue nitrite concentration, and
apoptosis assay.
LIPID PEROXIDATION ASSAY
Lipid peroxidation as index of the oxidative stress was determined
by assaying themalondialdheyde (MDA) production bymeans of the
thiobarbituric acid (TBA) test [Esterbauer and Cheeseman, 1990].
Brieﬂy: 1ml of supernatant of renal tissue treated or untreated with
998 HY ATTENUATES CsA-INDUCED NEPHROTOXICITY JOURNAL OF CELLULAR BIOCHEMISTRY
CsA, HY, and CsAþHY was mixed with 0.5mL of cold 30% (w/v)
trichloroacetic acid to precipitate proteins. The precipitate was
pelletted by centrifugation and 1ml of the supernatant was reacted
with 1.3ml of 0.5% (w/v) TBA at 858C for 40min. In TBA test
reaction, one molecule of MDA reacts with two molecules of TBA
with the production of a pink pigment having maximal absorbance
at 532–535 nm. Therefore, after cooling, the ﬂuorescence was read
at an excitation of 536 nm and an emission of 557 nm wavelengths
in a SPEX Fluoromax spectrophotoﬂuorimeter. The concentration of
MDA was calculated respect to a calibration curve (range: 0.5–
2 pmoles/ml), and results were expressed as pmoles of MDA/mg
proteins/24 h.
SOD ACTIVITY ASSAY
This assay for SOD activity involves inhibition of nitroblue
tetrazolium (NBT) reduction with xanthine-xanthine oxidase used
as a superoxide generator [Sun et al., 1988]. SOD is one of the most
important antioxidative enzymes. It catalyzes the dismutation of the
superoxide anion into hydrogen peroxide and molecular oxygen.
SOD activity was determined by the sensitive SOD assay that utilizes
a product a water-soluble formazan dye upon reduction with
superoxide anion SOD Activity with absorbance at 450 nm (Assay
Kit Fluka Products). Brieﬂy, 1ml of supernatant of renal tissue
treated or not treated with CsA, HY and CSAþHY was mixed. At the
end of incubation the supernatant were lysed and centrifuged at
14,000 g for 5min at 48C and on cytosol was determined cytosolic
and mitochondrial SOD activity. The starter of reaction by adding
Xanthine Solution. The absorbance readings every minute for
10min at room temperature. The rate of the reduction with a
superoxide anion is linearly related to the xanthine oxidase (XO)
activity, and is inhibited by SOD. The SOD activity was expressed as
% of inhibition respect to activity control. The % inhibition of the
rate of increase in absorbance is calculated as follows: %
Inhibition¼ (slope of activity control slope of sample) 100.
The amount of SOD that inhibited NBT reductionly 50% was deﬁned
to be 1 unit of enzyme activity.
CAT ACTIVITY ASSAY
CAT activity. The colorimetric assay, described by Sinha [1972] has
been applied to evaluate CAT activity. The method is based on the
principle that dichromate in acetic acid is reduced to chromate
acetate when heated in the presence of H2O2, with the formation of
perchromic acid as an unstable intermediate. The chromic acetate
thus produced is measured colorimetrically and absorbance was
read at 520 nm. Results are expressed as units for milligrams of
protein.
GPx ACTIVITY ASSAY
GPx activity. GPx activity was indirectly detected by a method
previously described by Lawrence and Burk [1976]. GPx requires
reduced glutathione, which is regenerated by glutathione reductase
using oxidized glutathione, a process that consumes NADPH. The
activity of GPx is deﬁned as micromoles of NADPH oxidized per
minute, taking into account that the millimolar absorption
coefﬁcient for NADPH at 340 nm is 6.22 Lmmol1 cm1. Results
are expressed as units for milligrams of protein.
APOPTOSIS ASSAY
To detect mono and oligo-nuclesomal DNA fragmentation, the Cell
Death Detection ELISA Plus (Boehringer Mannheim, Indianapolis,
IN) was used. The assay is based on a quantitative sandwich-
immunoassay principle using mouse monoclonal antibodies direct
against DNA and histones, respectively. Cytosol of kidney,
containing the fragmented DNA, were obtained by centrifugation
added to each well of 96-well plates coated with antihistone
antibody. After 90min of incubation at room temperature, the wells
were washed three times with PBS. Peroxidase conjugated anti-DNA
antibody was added to the wells, and incubated for 90min at room
temperature. After the wells were washed three times, 100ml of
colorimetric substrate was added and serial readings of optical
density at 405 and 490 nm was taken at 5min intervals.
TOTAL PROTEIN ASSAY
Total proteins were determined by the method of Lowry et al.
[1951].
STATISTICAL ANALYSIS
Data are expressed as mean standard deviation of 10 independent
determinations performed in duplicates. An error probability with
P< 0.05 (P< 0.05 (including P< 0.01 and 0.001) was selected as
signiﬁcant. All experiments were performed in duplicates and the
mean was used for analysis.
RESULTS
Figure 1 shows the values of blood pressure. Both CsA that HY-
induced hypertension in a time-dependent manner after 12 days of
treatment. After 24 days, in rats treated with CsA the SBP shifted
from 109.2 3.9 to 132.4 5.8mmHg and DBP shifted from
95.1 3.2 to 117.3 5.3mmHg while in rats treated with HY the
SBP shifted from 107.3 3.1 to 123.2 5.6mmHg and DBP shifted
from 92.1 3.6 to 106.5 5.8mmHg. The combination (HYþCsA)
induced an increase in SBP and DBP from 123.2 5.6mmHg (HY
alone) or 132.4 5.8mmHg (CsA alone) to 141.5 6.1mmHg, while
the DBP increased from 106.5 4.2mmHg (HY alone) or
117.3 5.7mmHg (CsA alone) to 129.4 5.3mmHg.
Table I shows the results of BUN levels of rats treated or untreated
for 0, 6, 12, 18, and 24 days with CsA or with HY alone or in
combination. The treatment with various drugs up to 18 days did not
produce any signiﬁcant change in BUN levels while treatment with
CsA for 24 days was able to signiﬁcantly increase the BUN levels
whose values shifted from 26.8 2.9 to 45.6 2.6mg/dl. The
treatment with HY after 24 days did not induce any signiﬁcant
change in BUN levels and values shifted from 29.7 4.8 to
37.8 5.1mg/dl. The HY used in association with CsA was able to
signiﬁcantly reduce the CsA-induced BUN increase shifting the
values from 45.6 2.6mg/dl (CsA alone) to 37.8 3.4mg/dl
(CsAþHY).
Table II shows the results on cholesterol levels of rats treated or
untreated for 0, 6, 12, 18, and 24 days with CsA or with HY alone or
in association. The treatment with various drugs up to 18 days did
not produce any signiﬁcant change in cholesterol levels while
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treatment with CsA for 24 days was able to signiﬁcantly increase
plasma cholesterol levels whose values shifted from 54.3 723 to
75.6 9.32mg/dl. Treatment with HY after 24 days of treatment did
not induce any signiﬁcant change with values that varied from
51.1 5.3 to 53.1 4.4mg/dl. The HY used in combination with
CsA was able to signiﬁcantly reduce the CsA-induced increase
shifting the cholesterol values from 75.6 9.3mg/dl (CsA alone) to
59.8 5.3mg/dl (CsAþHY).
Table III shows the results obtained on serum creatinine levels in
rats treated or untreated for 0, 6, 12, 18, and 24 days with CsA or
with HY alone or in combination. Even on this parameter, the
treatment with various drugs up to 18 days did not produce any
signiﬁcant change while treatment with CsA for 24 days was able to
signiﬁcantly increase the creatinine levels whose values shifted
from 0.35 0.02 to 0.46 0.01mg/dl of creatinine. Treatment with
HY after 24 days of treatment did not induce any signiﬁcant change
in serum creatinine (from 0.36 0.04 to 0.38 0.02mg/dl of
creatinine). HY used in association with CsA was able to
signiﬁcantly reduce the increase in creatinine induced by CsA
whose values shifted from 0.46 0.01mg/dl (CsA only) to
0.38 0.04mg/dl creatinine (CsAþHY).
CATALASE
Figure 2 shows the results on the CAT activity in kidney of rats
treated or untreated for 12 and 24 days with CsA or with HY alone or
in association. After 12 days of treatment with various drugs we did
not found any signiﬁcant variation in the CAT levels, while
treatment with CsA for 24 days was able to signiﬁcantly increase the
CAT activity in kidney from 0.42 0.032 to 0.8 0.054. The
treatment with HY alone had not signiﬁcant effect on CAT activity,
with values shifted from 0.42 0.042 to 0.51 0.053 while was able
to inhibit the effect of CsA by reducing signiﬁcantly the values by
0.8 0.054 (CsA alone) to 0.71 0.046 (CsAþHY).
SUPEROXIDE DISMUTASE
Figure 3 shows the results obtained on the SOD activity in rats
treated or untreated for 12 and 24 days with CsA or with HY alone or
in combination. After 12 days of treatment with various drugs no
Fig. 1. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die) used alone or in association on blood pressure values systolic (A) and diastolic (B) at 0–6–12–18–24 days of
treatment. Data represents mean SD of 10 animals. P< 0.05 versus control.
TABLE I. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die)
Used Alone or in Association on Plasma Urea at 0–6–12–18–24 Days
of Treatment
Treatment
Days
0 6 12 18 24
Control 26.8 4.5 24.8 3.5 28.2 2.9 29.6 3.3 30.3 2.7
CSA 26.8 2.9 36.4 4.6 35.9 3.9 39.5 4.8 45.6 2.2
HY 29.7 4.8 35.1 3.9 32.6 3.1 33.7 4.3 37.8 5.1
CSAþHY 26.1 2.9 31.9 4.8 31.5 4.4 36.1 2.9 37.8 3.0
Data are expressed as urea mg/dl and mean SD of 10 animals. P< 0.05 versus
control. P< 0.05 versus CSA alone.
TABLE II. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die)
Used Alone or in Association on Blood Cholesterol at 0–6–12–18–24
Days of Treatment
Treatment
Days
0 6 12 18 24
Control 53.9 6.1 52.8 5.8 54.6 4.9 54.2 6.0 54.3 5.8
CSA 54.3 7.2 56.3 5.5 50.6 5.3 56.4 6.2 75.6 9.3
HY 51.1 5.3 52.9 5.4 56.8 6.0 55.1 5.9 53.1 4.4
CSAþHY 52.8 4.9 53.1 5.7 51.6 4.6 53.8 5.7 59.8 5.3
Data are expressed as cholesterol mg/dl and mean SD of 10 animals. P< 0.05
versus control. P< 0.05 versus CSA alone.
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signiﬁcant variation in the SOD levels was observed, while treatment
with CsA for 24 days was able to signiﬁcantly reduce the SOD
activity in kidney. In fact, the % of inhibition shifted from 63.1 8.1
to 32.5 4.3. Treatment with HY alone did not change signiﬁcant
effect, with values varying from 63.1 8.1 to 62.3 6.9. The HY
used in combination with CsA was able to increase the SOD activity
with values shifted from 32.5 4.3 (CsA alone) to 41.2 5.3
(CsAþHY).
GLUTATHIONE PEROXIDASE
Figure 4 shows the results obtained on the GPx activity in rats
treated or untreated for 12 and 24 days with CsA or with HY alone or
in combination. After 12 days of treatment with various drugs no
signiﬁcant change was found in GPx levels while treatment with
CsA for 24 days was able to signiﬁcantly reduce the activity of GPx
in the kidney from 0.016 0.0031 to 0.008 0.0011.The treatment
with HY alone did not signiﬁcant effect (from 0.016 0.0031 to
0.015 0.0012), while the HY used in combination with CsA was
able to increase the CsA effects decreasing GPx values from
0.008 0.0011U/mg (CsA alone) to 0.011 0.009U/mg (CsAþHY)
of proteins.
MALONDIALDEHYDE
Figure 5 shows the results obtained in rats treated or untreated for 12
and 24 days with CsA or with HY used alone or in combination on
MDA levels. Administration of CsA produced an increase in the
levels of MDA after 12 days which became signiﬁcant after 24 days
of treatment increasing from 149.7 27.5 to 283.4 33.9 pmoles/
mg of proteins. HY used alone did not produce signiﬁcant changes
(from 149.7 27.5 to 151.7 21.9 pmoles/mg of proteins) but when
HY was used in combination with CsA was able to reduce the CsA
activity decreasing the MDA levels from 283.4 33.9 to
179.3 19.2 pmoles/mg of proteins.
TABLE III. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./
die) Used Alone or in Association on Serum Creatinine Obtained to
0–6–12–18–24 Days of Treatment
Treatment
Days
0 6 12 18 24
Control 0.34 0.03 0.36 0.02 0.35 0.02 0.37 0.03 0.36 0.03
CSA 0.35 0.02 0.34 0.02 0.37 0.02 0.41 0.02 0.46 0.01
HY 0.36 0.04 0.35 0.12 0.36 0.12 0.37 0.02 0.38 0.02
CSAþHY 0.34 0.02 0.33 0.02 0.38 0.03 0.38 0.05 0.38 0.04
Data are expressed as creatinine mg/dl and mean SD of 10 animals. P< 0.05
versus control. P< 0.05 versus CSA alone.
Fig. 2. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die) used alone
or in association on CAT levels in rat kidney after 12 and 24 days of treatment.
Data represents mean SD of 10 animals. P< 0.05 versus control. P< 0.05
versus CSA alone.
Fig. 3. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die) used alone
or in association on SOD levels in rat kidney after 12 and 24 days of treatment.
Data represents mean SD of 10 animals. P< 0.05 versus control. P< 0.05
versus CSA alone.
Fig. 4. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die) used alone
or in association on GPx levels in rat kidney after 12 and 24 days of treatment.
Data represents mean SD of 10 animals. P< 0.05 versus control. P< 0.05
versus CSA alone.
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APOPTOSIS
The apoptotic activity of different treatment protocols was evaluated
by assaying the levels of oligonucleosomes, in the cytosol of kidney
tissue. Figure 6 shows the absorbance values obtained in the cytosol
of kidneys of rats treated or untreated for 12 or 24 days with CsA or
HY alone or in combination. The treatment of various drugs for
12 days did not determined any signiﬁcant change. Treatment
with CsA for 24 days resulted in a signiﬁcant increase in the
apoptotic activity shifting absorbance values from 0.28 0.03 to
0.65 0.073. HY treatment did not induce any signiﬁcant change in
absorbance values (from 0.28 0.03 to 0.34 0.042) but used in
combination with CsA was able to signiﬁcantly reduce the CsA
induced increase in absorbance shifting from 0.65 0.073 (CsA
alone) to 0.43 0.052 (CsAþHY).
DISCUSSION
Therapy with CsA can lead to functional and structural changes in
the kidney of transplanted patients and in experimental animals
leading to renal dysfunction [Jackson et al., 1987] inducing a dose-
related in renal function. Histopathological changes including
interstitial ﬁbrosis and proximal and/or distal tubular damage have
been reported following treatment with CsA for extrarenal diseases
[Mason, 1990]. Our studies showed that chronic administration of
CsA caused a increase of blood pressure and a marked impairment of
renal function increasing signiﬁcantly the creatinine, cholesterol,
BUN levels, and inducing morphostructural changes of the tubular
vacuoles and necrosis, interstitial ﬁbrosis, and parietal cell
hyperplasia while HY did not led to enhancements (unpublished
data). HY treatment increased blood pressure, but signiﬁcantly
reduced CsA-induced effects on BUN, creatinine, and cholesterol. A
relationship between nephrotoxicity and oxidative stress has been
conﬁrmed in many experiments. In fact several antioxidants have
been used to attenuate CsA-induced nephrotoxicity [Naidu et al.,
1999; Tariq et al., 1999; Padi and Chopra, 2002]. Melatonin, a potent
hydroxyl radical scavenger, protected the CsA induced renal tubular
damage [Naidu et al., 1999]. Carvedilol, a beta-blocker with potent
free radical scavenger activity, reduced the MDA levels and
improved the renal dysfunction andmorphological changes induced
by CsA [Padi and Chopra, 2002]. Co-administration of catechin with
CsA signiﬁcantly reduced the lipid peroxidation and restored the
decreased glutathione levels induced by CsA [Anjaneyulu et al.,
2003]. The activity of glucocorticoids on oxidative stress has not
been well demonstrated. Infact Rajashree and Puvanakrishnan
[1998] have reported that antioxidant enzymes such as CAT, SOD,
GPx, and glutathione S-transferase exhibited a signiﬁcant decrease
in heart during dexametasone administration, whereas, in kidney,
they exhibited a signiﬁcant increase during treatment and after
withdrawal of dexametasone. Recently, it has been shown that
chronic isolation caused decreased in serum corticosterone and a
disproportion between CuZnSOD, peroxidases (CAT and GPx) and
GLR, thus promoting H2O2 accumulation and prooxidative state in
liver [Djordjevic et al., 2010]. In our study, we have shown that
chronic treatment with CsA signiﬁcantly reduced SOD and Gpx
activities in kidney, which accounts for the increased susceptibility
to oxidative stress of the cellular structures. Decreased SOD and Gpx
activities are probably due to the reduced synthesis or to an increase
of the turn-over of such enzymes [Deman et al., 2001; Yilmaz et al.,
2006]. In our experiments, though it has been demonstrated an
increase of CAT activity in the kidneys treated with CsA, the levels of
MDA were signiﬁcantly increased and HY was able to reduce
oxidative stress by reducing the levels of MDA and reverting the CsA
effect on SOD and GPx activity. Tubulointerstitial injury is the
prominent feature of chronic CsA nephropathy, and the major form
of cell death is apoptosis [Yang et al., 2002]. Apoptosis is an active
mechanism of cell clearance and plays a key role in the regulation of
cell number during development, in tissue homeostasis, and
following insults. In the kidney, apoptosis may be beneﬁcial [Ortiz
et al., 2000] but is deleterious if enough resident cells are lost [Li
et al., 2002]. CsA has been shown to induce apoptotic cell death not
only in T-lymphocytes, thus interfering with T-cell function [Ying
Fig. 5. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die) used alone
or in association on lipid peroxidation (MDA) in rat kidney after 12 and 24 days
of treatment. Data represents mean SD of 10 animals. P< 0.05 versus
control. P< 0.05 versus CSA alone.
Fig. 6. Effects of CsA (25mg/kg/s.c./die) or HY (5mg/kg/i.p./die) used alone
or in association on intracytosolic levels of nucleosomes in rat kidney after 12
and 24 days of treatment. Data represents mean of absorbance SD of 10
animals. P< 0.05 versus control. P< 0.05 versus CSA alone.
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et al., 2003], but also in some renal cells, resulting in the
deterioration of kidney structure. The literature data concerning
the effect of glucocorticoids on apoptosis are discordant and depend
on the tissue and the disease. The HY has a strong immunosuppres-
sive activity, in fact evokes immunosuppression by inducing the
apoptosis of T lymphocytes by activating supposed lysis genes or by
repressing the gene expression required for proliferation and growth
[Mazzali et al., 2001; Yang et al., 2003]. Several reports show that
the activity of glucocorticoids is different depending on the cell line,
infact cause cell cycle arrest and apoptosis in lymphoid cells
[Wasim et al., 2010], in carcinoma cells [Herr et al., 2003], instead
suppresses CsA-induced apoptosis but not cell cycle arrest in MDCK
cells [Jeon et al., 2005]. Our results showed that CsA administered in
rats for 24 days was able to induce apoptosis in renal cell and
that HY administered in combination reduced CsA induced
apoptosis. Our results suggest that the effect of HY on CsA-induced
apoptosis cold be due to its anti-oxidant effect. In conclusion, our
data demonstrate that, in rat kidney, CsA toxicity is due
to an oxidative stress overload which in turn induce lipid
peroxidation and determines oxidative stress-induced cell injury.
Treatment with HY effectively inhibits CsA-induced toxicity,
decreasing lipid peroxidation as well as apoptosis. Our ﬁndings
seem to suggest that glucocorticoids may be effective in reducing
CsA-induced nephrotoxicity at concentrations consistent with
therapeutic doses.
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